Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AndroMETa-GEA-977: ABBV-400 + Budigalimab + FOLFOX in First-Line Advanced GEA
jRCT2031240576Phase 2Active, not recruiting
- Sponsor
- AbbVie Inc.
- Start
- Dec 2024
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Small Molecules
01
Overview
Phase 2, randomised trial of telisotuzumab adizutecan in gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and esophageal adenocarcinoma (EAC), sponsored by AbbVie Inc. Primary endpoints: Progression-Free Survival (PFS) as Assessed by Investigator and Objective Response (OR) as Assessed by Investigator. Started Dec 2024; status: active, not recruiting.
02
Drugs
telisotuzumab adizutecan
03
Conditions
gastric adenocarcinomagastroesophageal junction adenocarcinomaesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on jRCT2031240576.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031240576.